{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:11Z","timestamp":1778617391377,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,5,5]],"date-time":"2014-05-05T00:00:00Z","timestamp":1399248000000},"content-version":"vor","delay-in-days":1130,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C237\/A7819"],"award-info":[{"award-number":["C237\/A7819"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C147\/A6058"],"award-info":[{"award-number":["C147\/A6058"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1593\/neo.101524","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T09:11:29Z","timestamp":1429780289000},"page":"339-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Emma J.","family":"Dean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Roulston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Ranson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Blackhall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1593\/neo.101524_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"24","key":"10.1593\/neo.101524_bib2","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1200\/JCO.2002.12.111","article-title":"Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up","volume":"20","author":"Sundstrom","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1593\/neo.101524_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc2297","article-title":"Diagnosing and exploiting cancer's addiction to blocks in apoptosis","volume":"8","author":"Letai","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1593\/neo.101524_bib4","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1367-5931(99)80073-8","article-title":"Novel anticancer drug discovery","volume":"3","author":"Buolamwini","year":"1999","journal-title":"Curr Opin Chem Biol"},{"issue":"1","key":"10.1593\/neo.101524_bib5","first-page":"6","article-title":"Expression of Bcl-2 in small cell lung carcinoma cells","volume":"54","author":"Ikegaki","year":"1994","journal-title":"Cancer Res"},{"issue":"2","key":"10.1593\/neo.101524_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/path.1711770206","article-title":"Expression of Bcl-2 oncogene protein is prevalent in small cell lung carcinomas","volume":"177","author":"Jiang","year":"1995","journal-title":"J Pathol"},{"issue":"3A","key":"10.1593\/neo.101524_bib7","first-page":"1689","article-title":"Immunohistochemical detection of bcl2, p53, mdm2 and p21\/waf1 proteins in small-cell lung carcinomas","volume":"18","author":"Stefanaki","year":"1998","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1593\/neo.101524_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0169-5002(96)00568-5","article-title":"Expression of Bcl-2-protein in small cell lung cancer","volume":"15","author":"Kaiser","year":"1996","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1593\/neo.101524_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.2004.10.148","article-title":"Phase I study of G3139, a Bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer","volume":"22","author":"Rudin","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1593\/neo.101524_bib10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2007.14.3461","article-title":"Randomized phase II study of carboplatin and etoposide with or without the Bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"49","key":"10.1593\/neo.101524_bib11","doi-asserted-by":"crossref","first-page":"19512","DOI":"10.1073\/pnas.0709443104","article-title":"Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis","volume":"104","author":"Nguyen","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1593\/neo.101524_bib12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","article-title":"Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins","volume":"13","author":"Zhai","year":"2006","journal-title":"Cell Death Differ"},{"issue":"10","key":"10.1593\/neo.101524_bib13","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1593\/neo.101524_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-007-0499-3","article-title":"A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells","volume":"61","author":"Li","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"10.1593\/neo.101524_bib15","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1182\/blood-2006-10-047951","article-title":"Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma","volume":"109","author":"Trudel","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1593\/neo.101524_bib16","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1101\/gad.1156903","article-title":"DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells","volume":"17","author":"Cuconati","year":"2003","journal-title":"Genes Dev"},{"issue":"8","key":"10.1593\/neo.101524_bib17","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/1535-7163.MCT-08-0285","article-title":"BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L\/TRAIL-induced apoptosis","volume":"7","author":"Mott","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1593\/neo.101524_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1078-0432.CCR-08-1575","article-title":"BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells","volume":"15","author":"Huang","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1593\/neo.101524_bib19","first-page":"465","article-title":"Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2\/neu and a Bcl-2 inhibitor","volume":"17","author":"Witters","year":"2007","journal-title":"Oncol Rep"},{"issue":"24","key":"10.1593\/neo.101524_bib20","doi-asserted-by":"crossref","first-page":"8295","DOI":"10.1158\/1078-0432.CCR-08-0999","article-title":"A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies","volume":"14","author":"Schimmer","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1593\/neo.101524_bib21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1593\/neo.101524_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-010-1265-5","article-title":"A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies","volume":"66","author":"Paik","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15s","key":"10.1593\/neo.101524_bib23","article-title":"A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC)","volume":"27","author":"Chiappori","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1593\/neo.101524_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2353\/ajpath.2009.090078","article-title":"Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy","volume":"175","author":"Hou","year":"2009","journal-title":"Am J Pathol"},{"issue":"suppl","key":"10.1593\/neo.101524_bib25","first-page":"184a","article-title":"Comparison of MTT, XTT, and a novel tetrazolium compound MTS for in vitro proliferation and chemosensitivity assays","volume":"3","author":"Riss","year":"1992","journal-title":"Mol Biol Cell"},{"issue":"18","key":"10.1593\/neo.101524_bib26","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1016\/S0021-9258(17)39978-7","article-title":"A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems","volume":"252","author":"Chou","year":"1977","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1593\/neo.101524_bib27","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","article-title":"Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737","volume":"67","author":"Tahir","year":"2007","journal-title":"Cancer Res"},{"issue":"7","key":"10.1593\/neo.101524_bib28","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1158\/0008-5472.CAN-07-5031","article-title":"Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer","volume":"68","author":"Hann","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1593\/neo.101524_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/(SICI)1096-9896(199903)187:4<410::AID-PATH266>3.0.CO;2-F","article-title":"In vivo patterns of Bcl-2 family protein expression in breast carcinomas in relation to apoptosis","volume":"187","author":"Rochaix","year":"1999","journal-title":"J Pathol"},{"issue":"3","key":"10.1593\/neo.101524_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00008390-199806000-00001","article-title":"Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines","volume":"8","author":"Selzer","year":"1998","journal-title":"Melanoma Res"},{"issue":"11","key":"10.1593\/neo.101524_bib31","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Campos","year":"1993","journal-title":"Blood"},{"issue":"12","key":"10.1593\/neo.101524_bib32","first-page":"3253","article-title":"Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma","volume":"54","author":"Dole","year":"1994","journal-title":"Cancer Res"},{"issue":"3","key":"10.1593\/neo.101524_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1593\/neo.101524_bib34","first-page":"1331","article-title":"Stress-resistance conferred by high level of Bcl-2 alpha protein in human B lymphoblastoid cell","volume":"4","author":"Tsujimoto","year":"1989","journal-title":"Oncogene"},{"issue":"21","key":"10.1593\/neo.101524_bib35","first-page":"6101","article-title":"An informatics approach identifying markers of chemosensitivity in human cancer cell lines","volume":"60","author":"Amundson","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"10.1593\/neo.101524_bib36","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","article-title":"Concurrent up-regulation of Bcl-xL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia","volume":"113","author":"Vogler","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1593\/neo.101524_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"e40","key":"10.1593\/neo.101524_bib38","first-page":"1","article-title":"A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy","volume":"1","author":"Placzek","year":"2010","journal-title":"Cell Death and Disease"},{"issue":"4","key":"10.1593\/neo.101524_bib39","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI39987","article-title":"Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance","volume":"120","author":"Bonapace","year":"2010","journal-title":"J Clin Invest"},{"issue":"15s","key":"10.1593\/neo.101524_bib40","article-title":"Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathwya using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL)","volume":"27","author":"Hernandez-Ilizaliturri","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1593\/neo.101524_bib41","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","article-title":"Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax)","volume":"68","author":"Konopleva","year":"2008","journal-title":"Cancer Res"},{"issue":"10","key":"10.1593\/neo.101524_bib42","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1593\/neo.08620","article-title":"Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drugsensitive tumor, testicular cancer","volume":"10","author":"de Haas","year":"2008","journal-title":"Neoplasia"},{"issue":"23","key":"10.1593\/neo.101524_bib43","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1158\/1078-0432.CCR-08-0678","article-title":"Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer","volume":"14","author":"Holdenrieder","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1593\/neo.101524_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1196\/annals.1448.012","article-title":"Clinical relevance of circulating nucleosomes in cancer","volume":"1137","author":"Holdenrieder","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"22","key":"10.1593\/neo.101524_bib45","doi-asserted-by":"crossref","first-page":"7304","DOI":"10.1158\/1078-0432.CCR-08-0111","article-title":"Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer","volume":"14","author":"Micha","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1593\/neo.101524_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1535-7163.MCT-07-2136","article-title":"Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity","volume":"7","author":"Cummings","year":"2008","journal-title":"Mol Cancer Ther"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558611800151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558611800151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:59:58Z","timestamp":1778615998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558611800151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S1476558611800151"],"URL":"https:\/\/doi.org\/10.1593\/neo.101524","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of Circulating Biomarkers of Obatoclax-Induced Cell Death in Patients with Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1593\/neo.101524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Neoplasia Press Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}